drugset / Trial / NCT00981227
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of the study is to assess the efficacy of eslicarbazepine acetate (ESL) as therapy for patients with post-herpetic neuralgia.
Timeline
- Start
- 2007-11
- Primary completion
- 2009-01
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eslicarbazepine acetate | Unknown | 400 mg | — |
| Subject | Eslicarbazepine acetate | Unknown | 600 mg | — |
| Subject | Eslicarbazepine acetate | Unknown | 800 mg | — |
| Subject | Eslicarbazepine acetate | Unknown | 1200 mg | — |